Parallax Volatility Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,200
Closed -$182K 3531
2022
Q3
$182K Buy
+1,200
New +$178K ﹤0.01% 2341
2020
Q4
Sell
-327,500
Closed -$21.3M 3421
2020
Q3
$21.3M Buy
327,500
+1,500
+0.5% +$98.3K 0.02% 708
2020
Q2
$23.8M Buy
326,000
+216,000
+196% +$11.5M 0.03% 466
2020
Q1
$3.74M Buy
+110,000
New +$5.03M ﹤0.01% 987
2019
Q2
Sell
-88,500
Closed -$4.55M 4321
2019
Q1
$4.55M Buy
88,500
+67,500
+321% +$2.92M 0.01% 714
2018
Q4
$777K Buy
+21,000
New +$757K ﹤0.01% 1391
2018
Q2
Sell
-34,000
Closed -$876K 4057
2018
Q1
$876K Buy
+34,000
New +$1.02M ﹤0.01% 989

Other funds holding BHVN

Parallax Volatility Advisers's BHVN Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,699 shares — an estimated $408K sold.

Parallax Volatility Advisers first reported a position in BHVN in Q4 2017 and held it in 10 quarters. The position peaked at $8.3M in Q2 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,699 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $408K.
  • Parallax Volatility Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 10 quarters.
  • Parallax Volatility Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $8.3M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.